Leap Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 30
Employees
  • Stock Symbol
  • LPTX
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $1.65
  • (As of Wednesday Closing)

Leap Therapeutics General Information

Description

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204, P205, and P103.

Contact Information

Website
www.leaptx.com
Formerly Known As
HealthCare Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge, MA 02141
  • United States
+1 (617) 000-0000

Leap Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Leap Therapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.65 $1.64 $1.43 - $3.24 $98.5M 59.7M 802K -$0.63

Leap Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 76,903 76,903 18,254 20,609
Revenue 1,500 1,500 0 0
EBITDA (27,536) (27,536) (33,146) (23,497)
Net Income (27,514) (27,514) (32,900) (23,138)
Total Assets 54,371 54,371 7,448 19,074
Total Debt 552 552 1,026 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Leap Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Leap Therapeutics‘s full profile, request access.

Request a free trial

Leap Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Leap Therapeutics‘s full profile, request access.

Request a free trial

Leap Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer b
Biotechnology
Cambridge, MA
30 As of 2020
00000
000000 - 000 00000

0000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

0000000

sum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
0000000000000
Summit, NJ
0000 As of 0000
000.00
00.00 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Leap Therapeutics Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncorus Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000 Formerly VC-backed Summit, NJ 0000 000.00 000000&0 000.00
0000 0000000000000 Venture Capital-Backed South San Francisco, CA 00 0000 0000000000 0000
0000000 Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 00000000000 00000
You’re viewing 5 of 34 competitors. Get the full list »

Leap Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Douglas Onsi JD Chief Executive Officer, President & Board Member
Augustine Lawlor Chief Operating Officer, Operations
Jonathan Miller Director, Business Development & Finance
Mark O'Mahony Executive
Christine Granfield Vice President & Head of Regulatory Affairs and Quality
You’re viewing 5 of 8 executive team members. Get the full list »

Leap Therapeutics Board Members (9)

Name Representing Role Since
Christopher Mirabelli Ph.D Leap Therapeutics Chairman & Board Member 000 0000
Douglas Onsi JD Leap Therapeutics Chief Executive Officer, President & Board Member 000 0000
James Cavanaugh Ph.D HealthCare Ventures Board Member 000 0000
Joseph Loscalzo Ph.D Leap Therapeutics Board Member 000 0000
Monica Bertagnolli Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Leap Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leap Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Leap Therapeutics‘s full profile, request access.

Request a free trial

Leap Therapeutics Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 23-Jan-2017 000000000000000000 Biotechnology 00000000000 000000000 00.0
0000 21-Jan-2016 000000 00 000000 Drug Discovery 0000000 0000 00
HealthCare Pharmaceuticals 21-Jan-2016 Merger of Equals Biotechnology
To view Leap Therapeutics’s complete acquisitions history, request access »